Eidos Therapeutics
AcquiredSan Francisco, United States · Founded 2016 · $91.0M raised
- Headquarters
- San Francisco, California
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2B
- Total Funding
- $91.0M
- Last Round
- $64.0M Series BApr 2018
- Rounds
- 2
About
Clinical-stage biopharmaceutical company developing therapies for transthyretin amyloidosis.
Summary
Eidos Therapeutics is a Biotech company based in San Francisco, United States, founded in 2016. It has raised $91.0M in total across 2 rounds, most recently a $64.0M Series B round in Apr 2018. Investors include BridgeBio, RA Capital Management and Viking Global.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2021
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.